Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Economic impact of Gastrointestinal stromal tumor on families
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Gastrointestinal stromal tumor

Economic impact of Gastrointestinal stromal tumor on families

1 evidence topic · 1 source

Individual family account: medication costs and copay assistance

“hundreds of dollars just for a single pill” (opens the source at this quote in a new tab)
“This funding is enough to cover my mother’s drug copay liability for 2022” (opens the source at this quote in a new tab)